Could your dementia target benefit from further investment? We provide funding, expertise and resources for promising dementia research. Request the application form. NEXT DEADLINE: 23 April 2018**
What is the Dementia Consortium?
The Dementia Consortium supports collaborative target validation and drug discovery projects from academia and SMEs. We offer a unique collaborative model bringing together the charity and industry sectors to help accelerate development of therapies for novel dementia targets.
What do we offer?
The Dementia Consortium provides drug discovery resources, project management, industry expertise and tools as well as full funding support for projects. We can support small molecule or antibody-based strategies and aim to generate tools to achieve preclinical target validation. Our ultimate goal is to progress successful projects from laboratories towards the clinic.
**Applications to collaborate with the Dementia Consortium are open globally to academic researchers and SMEs and are reviewed six times per year. However, based on the success of the first three years of the Dementia Consortium we are extending the Dementia Consortium for a further three years. To enable us to transition between these two phases the next deadline for Dementia Consortium funding applications will be 23rd April 2018.
What we are looking for:
- Projects focused on novel molecular targets in any neurodegenerative disease (including Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, tauopathies, vascular dementia, Amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntingdon’s disease)
- Evidence linking the target to human disease and confidence that target modulation would have a therapeutic effect
- Collaborators with strong biology expertise and access to enabling assays, reagents and disease models
The following projects are not in scope for funding:
- Projects focused on well-studied targets and pathways for neurodegenerative diseases
- In vivo PK studies, preclinical proof-of-concept studies or IND-enabling studies
- Repurposing of existing drugs (although we will consider optimisation of tool / literature compounds to improve selectivity, potency, bioavailability, etc)
- Non-pharmacological interventions (e.g. diet or exercise or other behavioural changes)
Previous experience in drug discovery is not required, nor do you need to have any in-house capability for carrying out drug development. The Consortium, through LifeArc, is able to provide all of the assay development, screening and medicinal chemistry resources required to develop novel compounds or antibodies against the target.
If you are not sure if your project is eligible or require more information please get in touch with us.
23rd April 2018**
The case for the Dementia Consortium
Neurodegenerative diseases that cause dementia are our biggest medical challenge. Dementia affects 820,000 people in the UK today and nearly 40 million worldwide. As populations age, the worldwide prevalence of dementia is expected to double every twenty years. Millions of lives will be blighted by these diseases. As well as the enormous social cost, neurodegenerative disease carries an enormous economic impact. In the UK alone, dementia has an economic cost of £23bn, which is greater than heart disease and cancer combined. The Dementia Consortium is focused on fast-tracking new treatments to find an answer to the neurodegenerative diseases that cause dementia.